[
  {
    "ts": null,
    "headline": "US FDA declines to approve higher dose of Biogen's genetic disorder drug",
    "summary": "Biogen said the FDA requested revisions to the Chemistry Manufacturing and Controls module in its so-called \"complete response letter\" but did not identify deficiencies in the clinical data supporting the high-dose regimen.  The company plans to resubmit the application promptly based on readily available information.",
    "url": "https://finnhub.io/api/news?id=2bffe56c4bd95ea7141bb7093bf652dd61db8353a58e3038e433de2a913d54f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758665916,
      "headline": "US FDA declines to approve higher dose of Biogen's genetic disorder drug",
      "id": 136916236,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen said the FDA requested revisions to the Chemistry Manufacturing and Controls module in its so-called \"complete response letter\" but did not identify deficiencies in the clinical data supporting the high-dose regimen.  The company plans to resubmit the application promptly based on readily available information.",
      "url": "https://finnhub.io/api/news?id=2bffe56c4bd95ea7141bb7093bf652dd61db8353a58e3038e433de2a913d54f6"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen",
    "summary": "CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA. The letter did not",
    "url": "https://finnhub.io/api/news?id=f4ea61ba3ca618d639543c78f230ce4f361794965eb0284e1245ed8aa6b1ce2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758659400,
      "headline": "Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen",
      "id": 136855722,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA). The FDA letter requested an update to the technical information be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA. The letter did not",
      "url": "https://finnhub.io/api/news?id=f4ea61ba3ca618d639543c78f230ce4f361794965eb0284e1245ed8aa6b1ce2e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Asked to Update FDA Application",
    "summary": "Biogen Asked to Update FDA Application",
    "url": "https://finnhub.io/api/news?id=13eaede0852ff294f0f65a4b2816efa95df6b833311e9e72a40bdddf5c426c99",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758646260,
      "headline": "Biogen Asked to Update FDA Application",
      "id": 136879033,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Asked to Update FDA Application",
      "url": "https://finnhub.io/api/news?id=13eaede0852ff294f0f65a4b2816efa95df6b833311e9e72a40bdddf5c426c99"
    }
  }
]